NEW YORK (GenomeWeb) – Myriad Genetics this week denied allegations of patent infringement levied against it in a US District Court by LabCorp subsidiary Esoterix Genetic Laboratories (EGL), arguing that its myRisk Hereditary Cancer panel and related services do not make use of the digital PCR technology covered in the intellectual property at the center of the dispute.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.